Found: 18
Select item for more details and to access through your institution.
Alternative processing of human HTT mRNA with implications for Huntington's disease therapeutics.
- Published in:
- Brain: A Journal of Neurology, 2022, v. 145, n. 12, p. 4409, doi. 10.1093/brain/awac241
- By:
- Publication type:
- Article
Results of the first‐in‐human, randomized, double‐blind, placebo‐controlled phase 1b study of lumbar intrathecal bolus administrations of antisense oligonucleotide (ISIS 814907; BIIB080) targeting tau mRNA in patients with mild Alzheimer's disease
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.051871
- By:
- Publication type:
- Article
DISCOVERY AND EARLY CLINICAL DEVELOPMENT OF IONIS-MAPTRX, THE FIRST TAU-LOWERING ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH MILD AD.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P600, doi. 10.1016/j.jalz.2017.07.242
- By:
- Publication type:
- Article
Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides.
- Published in:
- Biomolecules (2218-273X), 2020, v. 10, n. 1, p. 1, doi. 10.3390/biom10010001
- By:
- Publication type:
- Article
In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides.
- Published in:
- Molecular Therapy, 2014, v. 22, n. 12, p. 2093, doi. 10.1038/mt.2014.153
- By:
- Publication type:
- Article
Huntingtin-Lowering Therapies for Huntington Disease: A Review of the Evidence of Potential Benefits and Risks.
- Published in:
- JAMA Neurology, 2020, v. 77, n. 6, p. 764, doi. 10.1001/jamaneurol.2020.0299
- By:
- Publication type:
- Article
Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models.
- Published in:
- 2018
- By:
- Publication type:
- journal article
PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Protein production is an early biomarker for RNA‐targeted therapies.
- Published in:
- Annals of Clinical & Translational Neurology, 2018, v. 5, n. 12, p. 1492, doi. 10.1002/acn3.657
- By:
- Publication type:
- Article
Huntingtin suppression restores cognitive function in a mouse model of Huntington disease.
- Published in:
- Science Translational Medicine, 2018, v. 10, n. 461, p. 1, doi. 10.1126/scitranslmed.aar3959
- By:
- Publication type:
- Article
Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy.
- Published in:
- Science Translational Medicine, 2017, v. 9, n. 374, p. 1, doi. 10.1126/scitranslmed.aag0481
- By:
- Publication type:
- Article
Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles.
- Published in:
- Human Molecular Genetics, 2017, v. 26, n. 6, p. 1115, doi. 10.1093/hmg/ddx021
- By:
- Publication type:
- Article
Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.
- Published in:
- Human Molecular Genetics, 2016, v. 25, n. R1, p. R53, doi. 10.1093/hmg/ddv442
- By:
- Publication type:
- Article
A single-cell map of antisense oligonucleotide activity in the brain.
- Published in:
- Nucleic Acids Research, 2023, v. 51, n. 14, p. 7109, doi. 10.1093/nar/gkad371
- By:
- Publication type:
- Article
MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models.
- Published in:
- Journal of Neuroscience, 2017, v. 37, n. 22, p. 5574, doi. 10.1523/JNEUROSCI.3582-16.2017
- By:
- Publication type:
- Article
C-termini of P/Q-type Ca2+ channel α1A subunits translocate to nuclei and promote polyglutamine-mediated toxicity.
- Published in:
- Human Molecular Genetics, 2006, v. 15, n. 10, p. 1587, doi. 10.1093/hmg/ddl080
- By:
- Publication type:
- Article
Peripheral huntingtin silencing does not ameliorate central signs of disease in the B6.Htt<sup>Q111/+</sup> mouse model of Huntington’s disease.
- Published in:
- PLoS ONE, 2017, v. 12, n. 4, p. 1, doi. 10.1371/journal.pone.0175968
- By:
- Publication type:
- Article